Xeltis has been recognized as a breakthrough medtech start-up.

Xeltis developed the world’s most advanced polymer-based platform of restorative cardiovascular devices. The devices naturally evolve into living blood vessels or heart valves, when colonized by patient’s own tissue.

This therapeutic approach is called Endogenous Tissue Restoration (ETR). With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.

ETR is enabled by the porous structure of Xeltis’ devices, which are made of bioabsorbable polymers, based on Nobel-prize awarded science.